NEWTON, Mass., July 17, 2026
Inflammasome Therapeutics announced positive six-month Phase 2 clinical trial results for K8 (kamuvudine-8), its investigational dual inflammasome inhibitor being developed for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). The study demonstrated that patients receiving the 0.7 mg K8 implant experienced a 54% reduction in the mean rate of geographic atrophy lesion growth compared with untreated control eyes, achieving statistical significance (p=0.016) using the FDA-preferred slope analysis. In a prespecified analysis of patients with extrafoveal lesions, K8 also produced a 4.0-letter adjusted advantage in best-corrected visual acuity (BCVA) over controls (p=0.004), representing a significant functional benefit alongside anatomical improvement. Importantly, the study identified no safety signals of concern, with no drug-related serious adverse events, dose-limiting toxicities, intraocular inflammation, retinal vasculitis, endophthalmitis, or neovascular age-related macular degeneration reported during the six-month evaluation period. The findings position K8 as a promising investigational therapy with the potential to address one of the largest unmet needs in retinal disease.
K8 Demonstrates Significant Reduction in Disease Progression and Vision Loss
The multicenter Phase 2 trial enrolled 30 patients with bilateral geographic atrophy, representing 60 study eyes across nine U.S. clinical centers. Participants received a bioerodible sustained-release intravitreal K8 implant in the worse-seeing eye at baseline and again at Month 3, while the fellow eye served as an untreated control. Three dose levels—0.3 mg, 0.7 mg, and 1.05 mg—were evaluated, with the 0.7 mg cohort demonstrating the strongest efficacy by reducing the progression of geographic atrophy by 54% compared with pooled control eyes over six months. Investigators also reported that all three dose cohorts slowed lesion growth to a greater extent than historical results reported for currently approved geographic atrophy therapies. Unlike existing treatments that have shown approximately 13–14% reductions in lesion growth without demonstrating visual acuity improvement in pivotal trials, K8 achieved both structural and functional benefits, suggesting that its unique dual inflammasome inhibition mechanism may help preserve retinal tissue while improving retinal cell function.
Novel Dual Inflammasome Inhibitor Shows Strong Safety and Practical Advantages
K8 (kamuvudine-8) is designed as a bioerodible sustained-release intravitreal implant that inhibits convergent inflammasome pathways responsible for chronic inflammation, retinal degeneration, and cell death associated with geographic atrophy. Delivered through a 24-gauge in-office injector, the implant provides sustained drug release over approximately three months, supporting a convenient once-quarterly dosing schedule. The product is supplied in a preloaded injector, requires no refrigeration or cold-chain storage, and eliminates the need for medication preparation before administration. Throughout the Phase 2 study, investigators observed an encouraging safety profile with no serious drug-related adverse events, no dose-limiting toxicities, and no cases of major ocular complications commonly associated with intravitreal therapies. Experts presenting the findings at the American Society of Retina Specialists (ASRS) Annual Meeting noted that the combination of reduced lesion growth and improved visual function suggests K8 may both protect retinal cells from degeneration and restore function in stressed retinal tissue, representing a potentially differentiated therapeutic approach for patients with geographic atrophy.
Advertisement
Company Plans Global Phase 3 Program Following Strong Clinical Results
Following the encouraging Phase 2 findings, Inflammasome Therapeutics plans to initiate a global pivotal Phase 3 clinical development program while engaging regulatory authorities to finalize the study design. Independent retina specialists described the results as highly encouraging and emphasized the importance of confirming both the anatomical benefits and visual acuity improvements in larger clinical trials. If replicated during Phase 3 development, K8 could become a highly differentiated treatment option capable of slowing disease progression while preserving vision in patients with geographic atrophy, a condition affecting approximately eight million people worldwide. Beyond ophthalmology, the company’s kamuvudine platform is also being investigated for neurodegenerative diseases, reflecting the broader therapeutic potential of dual inflammasome inhibition. Although K8 remains investigational and has not yet received regulatory approval, the latest clinical data provide strong support for advancing the program toward late-stage development and potentially establishing a new standard of care for patients with advanced dry age-related macular degeneration.
Source: Inflammasome Therapeutics, press release
